BioSpace News Archive

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today reports financial results for the quarter that ended September 30, 2020, along with an update on the Company’s key pipeline developments, business operations and upcoming milestones.

Alzinova AB today announces the upcoming clinical study with the vaccine candidate ALZ-101 at the scientific congress Clinical Trials in Alzheimer’s Disease (CTAD). The planned study will be conducted in patients with early Alzheimer’s disease and is expected to commence during the second quarter 2021. The study design is today p

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that management is scheduled to participate in three upcoming virtual investor conferences: A presentation by Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, at the Credit Suisse 29 th Annual Healthcare Conference on November 11, 2020 at 10:15 a.m. ET

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today reported financial results for the third quarter of 2020 ended September 30, 2020 and provided an update on the Company’s recent and anticipated future developments.

Enrollment Ongoing in Phase 1 Trials of ALLO-501 (ALPHA), ALLO-501A (ALPHA2) and ALLO-715 (UNIVERSAL) Initial Phase 1 Results from the UNIVERSAL Trial in Relapsed/Refractory Multiple Myeloma to be Presented at a Medical Meeting in Q4 2020 In 1H 2021, Initial ALLO-501A Data and Updated ALLO-501 Results in Non-Hodgkin Lymphoma are Planned in Preparation for a Potential Pivotal Study Initiation of ALLO-501A in 2021 Three Investigational New Drug (IND) Applications to be Submitted; Two in Q4 2020

– T rading on Nasdaq Capital Market is expected to begin on November 5, 2020 – – Company receives additional 180-day grace period, until May 3, 2021, to satisfy the $1.00 bid price requirement to maintain Nasdaq listing –

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that Anna Protopapas, President and Chief Executive Officer, will present at the 29 th Annual Credit Suisse Virtual Healthcare Conference on Wednesday, November 11, at 11:00 a.m. ET. A live webcast of

BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT) an emerging biotech company that is beginning clinical trials of AP-003, its COVID-19 inhalation therapeutic, announced today that it has selected Florence Healthcare to provide its electronic Trial Master File (‘eTMF’) for the conduct of the AP-003 trial. The Florence platform will simplify and accelerate forthcoming clinical trial by streamlining interna

Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating cancer patients, announces that it will release financial results for the three and nine months ended September 30, 2020 after the market closes on Thursday, November 12, 2020 . The Company will host a conf

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB, and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, today announced that management will present at two investor conferences in November. Credit Suisse 29th A